---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-24-000027"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:06:22.016922+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease

## Summary
- Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.
- Pain and function scales (VAS, ODI, RMDQ, FRI) show positive trend vs baseline at both follow-up points.
- No notable safety signals observed in the ongoing study for chronic lumbar disc disease.
- Company will host webcasted conference call today Feb 5 at 8:30am ET to discuss data and clinical update.

## SEC filing metadata
- accession: 0001021771-24-000027
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000027/0001021771-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000027/brt8k2524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-24-000027
- JSON: https://secwatch.observer/filing/0001021771-24-000027.json
- Plain text: https://secwatch.observer/filing/0001021771-24-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.